Alteration in the sensitivity to crizotinib by Na⁺/H⁺ exchanger regulatory factor 1 is dependent to its subcellular localization in ALK-positive lung cancers.

ABSTRACT:

Background

Na⁺/H⁺ exchanger regulatory factor 1 (NHERF1) is an important scaffold protein participates in the modulation of a variety of intracellular signal pathways. NHERF1 was able to enhance the effects of chemo-drugs in breast and cervical cancer cells. Anaplastic lymphoma kinase (ALK) fusion mutations are validated molecules targeted therapy in lung cancers, where crizotinib can be used as the specific inhibitor to suppress tumor progression. However, due to the less frequent occurrence of ALK mutations and the complexity for factors to determine drug responses, the genes that could alter crizotinib sensitivity are unclear.

Methods

Both ALK-translocated and ALK-negative lung adenocarcinoma specimens in tissue sections were collected for immunohist

SUBMITTER: Yang F 

PROVIDER: S-EPMC7068933 | biostudies-literature | 2020 Mar

REPOSITORIES: biostudies-literature